MedTrace Logo

The Mass Balance and Biotransformation of [14C] Vicagrel in Healthy Man

NCT04143750 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 6

Last updated 2020-04-03

No results posted yet for this study

Summary

This study was designed to evaluate the mass balance and biotransformation after single-dose of \[14C\]Vicagrel orally in Chinese healthy male volunteers, revealing the overall pharmacokinetic characteristics of vicagrel in humans, and providing a reference for the rational administration.

Conditions

  • Healthy Male Adult

Interventions

DRUG

[14C]Vicagrel

Take a suspension of 20 mg vicagrel ,containing about 120 μCi \[14C\]Vicagrel, in fasting within 5 minutes

Sponsors & Collaborators

  • Jiangsu vcare pharmaceutical technology co., LTD

    lead INDUSTRY

Principal Investigators

  • Liyan Miao, PhD · First Affiliated Hospital of Suzhou Medical College

Study Design

Allocation
NA
Purpose
OTHER
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
45 Years
Sex
MALE
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2019-11-11
Primary Completion
2019-12-29
Completion
2020-01-14

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04143750 on ClinicalTrials.gov